Cicor Technologies (CICN) Investor Presentation summary

Business overview and market focus

• Operates in Industrial, Medical, and Aerospace & Defence sectors, with 84% of sales from these strategic markets in 2023.

• Drives technology in miniaturization, automation, and mission-critical electronics, serving high-growth verticals like smart drug delivery and robotics.

• European market leader in Aerospace & Defence EMS, with a 23% share of pro forma 2024 sales.

• Medical sector accounts for 25% of pro forma 2024 sales, ranking fourth in Europe.

• Industrial sector represents 37% of pro forma 2024 sales, focusing on robotics, sensors, and control systems.

Financial performance and key figures

• Achieved 24.5% sales growth in 2023, reaching CHF 390 million, with 11.1% organic growth.

• EBITDA margin improved to 11.6%, with EBITDA up 39.8% and EBIT up 65.1% year-over-year.

• Net profit increased by 28.1% to CHF 11.8 million; earnings per share rose to CHF 2.66.

• Net debt decreased to CHF 43.5 million, with a gearing ratio of 33.1% and equity ratio at 38.2%.

• Return on invested capital (ROIC) rose to 14.4%, driven by revenue growth and capital efficiency.

M&A strategy and recent acquisitions

• Pursues a value-accretive buy-and-build strategy, focusing on consolidating the fragmented EMS market.

• Completed acquisitions in 2023–2024: STS Defence (UK), Evolution Medtec (Romania), and three TT Electronics sites (UK, China).

• Acquisitions enhance capabilities in mission-critical electronics, medical technology, and expand geographic reach.

• Maintains a strong M&A pipeline and financial foundation for further inorganic growth.

• Integration of acquired companies supports sales and earnings growth.